Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed)

摘要: Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [PCV13] is approved for protection against pneumococcal disease in children aged 6 weeks to 5 years and adults ≥50 years. In randomized trials 60–64 (not previously vaccinated with 23-valent [PPV23]) ≥70 (previously PPV23), PCV13 was non-inferior PPV23 opsonophagocytic assay (OPA) geometric mean titres (GMTs) all 12 serotypes common the two vaccines. More than recipients had ≥4-fold increases serotype 6A OPA GMTs (serotype not included PPV23). also higher met superiority criteria most serotypes. Adults 50–59 antibody responses that were noninferior those administered concomitantly trivalent inactivated influenza or ≥65 produced following sequential administration, except strain A/H3N2 19F Antibody numerically although clinical significance of this unknown. Adverse events within 14 days vaccination mostly mild-to-moderate severity, serious occurring 0.2–1.4% 0.4–1.7% recipients.